Bristol-Myers Squibb BMY Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenues by Product | ||||||
| Abraxane | $50M-40.5% | $84M+13.5% | $74M-29.5% | $105M0.0% | $105M-39.7% | |
| Breyanzi | $411M+4.8% | $392M+9.2% | $359M+4.4% | $344M+30.8% | $263M0.0% | |
| Camzyos | $314M-11.3% | $354M+19.6% | $296M+13.8% | $260M+63.5% | $159M-28.7% | |
| Cobenfy | $56M+12.0% | $50M+16.3% | $43M+22.9% | $35M+29.6% | $27M+170% | |
| Eliquis | $4.14B+19.8% | $3.45B-7.8% | $3.75B+1.8% | $3.68B+3.2% | $3.57B+11.6% | |
| Krazati | $50M-10.7% | $56M+5.7% | $53M+10.4% | $48M0.0% | $48M+23.1% | |
| Opdivo Qvantig | $163M+22.6% | $133M+98.5% | $67M+123% | $30M+233% | $9M— | |
| Opdivo | $2.15B-20.3% | $2.69B+6.4% | $2.53B-1.1% | $2.56B+13.0% | $2.27B-8.6% | |
| Opdualag | $295M-15.7% | $350M+17.1% | $299M+5.3% | $284M+12.7% | $252M-0.8% | |
| Orencia | $818M-18.8% | $1.01B+4.6% | $964M+0.1% | $963M+25.1% | $770M-23.0% | |
| Other Growth products | $581M+8.4% | $536M+4.3% | $514M+9.4% | $470M-7.3% | $507M-3.8% | |
| Other Legacy products | $156M-21.6% | $199M+12.4% | $177M-20.6% | $223M+12.1% | $199M-20.4% | |
| Other revenue | -$15M— | —— | —— | —— | $0— | |
| Pomalyst/Imnovid | $513M-25.9% | $692M+2.5% | $675M-4.7% | $708M+7.6% | $658M-20.0% | |
| Reblozyl | $555M-16.7% | $666M+8.3% | $615M+8.3% | $568M+18.8% | $478M-12.6% | |
| Revlimid | $349M-42.0% | $602M+4.7% | $575M-31.4% | $838M-10.5% | $936M-30.1% | |
| Sotyktu | $69M-18.8% | $85M+6.3% | $80M+14.3% | $70M+27.3% | $55M-33.7% | |
| Sprycel | $73M-8.8% | $80M-32.8% | $119M-0.8% | $120M-31.4% | $175M-11.6% | |
| Yervoy | $651M-19.6% | $810M+9.6% | $739M+1.5% | $728M+16.7% | $624M-7.6% | |
| Zeposia | $118M-25.8% | $159M-1.2% | $161M+7.3% | $150M+40.2% | $107M-32.3% | |
| Total Revenues by Geography | ||||||
| International | $3.44B-5.3% | $3.64B+0.9% | $3.6B+3.5% | $3.48B+11.9% | $3.11B-8.4% | |
| Other | $257M-16.8% | $309M+6.6% | $290M+7.4% | $270M+23.9% | $218M-37.7% | |
| United States | $7.79B-9.0% | $8.56B+2.7% | $8.33B-2.2% | $8.52B+8.2% | $7.87B-8.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bristol-Myers Squibb break its business down?
- Bristol-Myers Squibb (BMY) reports total revenues by product across 20 parts — Abraxane, Breyanzi, Camzyos, Cobenfy and Eliquis. Each is extracted from the segment footnotes and tracked over time.
- Where does Bristol-Myers Squibb's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bristol-Myers Squibb's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
